Joerg Moeller via Getty
February 12, 2020 07:09 AM EST
Deals
R&D

Bay­er hands over a big drug R&D op­er­a­tion to CRO amid an on­go­ing re­struc­tur­ing ef­fort

John Carroll

Editor & Founder

Bay­er’s 400-strong small mol­e­cule R&D team is be­ing carved out and hand­ed to a CRO, where they’ll con­tin­ue to work for Bay­er.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times